3SBio: Is this Chinese Biotechnology Stock a Buy? – Barron’s

Posted: Published on April 27th, 2017

This post was added by Dr P. Richardson


Barron's
3SBio: Is this Chinese Biotechnology Stock a Buy?
Barron's
Shenyang-based 3SBio (1530.HK) is a biopharmaceutical pioneer that offers a unique play on China's rising demand for healthcare. The company is best known for its rheumatoid arthritis drug YSP, which accounts for 33% of revenues, and TPIAO, ...

See the article here:
3SBio: Is this Chinese Biotechnology Stock a Buy? - Barron's

Related Posts
This entry was posted in Biotechnology. Bookmark the permalink.

Comments are closed.